<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01594385</url>
  </required_header>
  <id_info>
    <org_study_id>2009H0311</org_study_id>
    <nct_id>NCT01594385</nct_id>
  </id_info>
  <brief_title>Seprafilm in Open Abdomens: a Study of Wound and Adhesion Characteristics in Trauma Damage Control Patients</brief_title>
  <acronym>OASIT</acronym>
  <official_title>Seprafilm in Open Abdomens: a Prospective Evaluation of Wound and Adhesion Characteristics in Trauma Damage Control (OASIT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stan Stawicki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Luke's Hospital and Health Network, Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to test the effects of Seprafilm adhesion barrier on patients who
      are undergoing open abdomen damage control management for traumatic injuries when compared to
      no adhesion barrier use. Specifically, the researchers wish to study the effects of Seprafilm
      adhesion barrier on:

        -  the number and intensity of adhesions,

        -  whether there is any difference between treatment groups (Seprafilm vs. no Seprafilm)
           who go on to successful definitive abdominal closure,

        -  rate of occurrence of secondary complications (such as abscesses) associated with short-
           and long-term beneficial effects of reducing adhesion formation,and

        -  whether there is any difference between treatment groups regarding patient functional
           recovery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data to be analyzed includes:

      Age, gender, traumatic injuries, trauma alert level, procedure information, length of
      hospital stay, length of ICU stay, interval between admission and initial operation, interval
      between operations, whether operation took place during the day or night, duration of
      operation in minutes, number of surgeons present during the operation, description of the
      initial operation, justification for using damage control approach, complications noted,
      injuries missed or delayed in diagnosis, Acute Physiology and Chronic Health Evaluation II
      (APACHE II) calculations at various time points, Simplified Acute Physiology Score (SAPS II)
      calculations at various time points, Glasgow Coma Score (GCS) calculations at various time
      points, changes in GCS at over time, Injury Severity Score (ISS) at various time points,
      Abbreviated Injury Scale (AIS) at various time points, Penetrating Abdominal Trauma Index
      score (if applicable) at various time points, complete blood count (CBC) results at various
      time points, blood chemistry results at various time points, blood gas results at various
      time points, subject randomization information, number of operations, adhesion scores (Zuhlke
      and Yaacobi) for each operative procedure, contamination score for each operative procedure,
      diagnosis and description of sub-procedures for each operative procedure, wound
      characteristics from the start and end of all operative procedures (e.g. length and width of
      the fascia and skin), type of abdominal coverage or closure, discharge destination (e.g.
      home, short term rehabilitation facility, etc.), Functional Outcome Measure score, Glasgow
      Outcome Score (GOS) at various time points, number and interval of post discharge follow-up
      visits, wound characteristics since discharge at several time points and
      complications/complaints noted since discharge at several time points.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adhesion Characteristics</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Zuhlke adhesion score (1 - minimum to 4 - maximum)
= filmy adhesions, easy to separate by blunt dissection
= stronger adhesions; blunt dissection possible, partly sharp dissection necessary; beginning of vascularization
= strong adhesions; lysis possible by sharp dissection only; clear vascularization
= very strong adhesions; lysis possible by sharp dissection only; organs strongly attached with severe adhesions; damage to organs hardly preventable</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wound Healing Characteristics</measure>
    <time_frame>Participants will be followed until their open abdomen is closed. Depending on the nature and severity of the wound, this period may last as long as 1 year after the patient has been discharged.</time_frame>
    <description>There will not be a fixed duration of outpatient follow-up (fixed follow-up in trauma patients is not practical due to the unpredictable nature of trauma population), an average (mean) follow-up will be determined for the entire cohort of patients for the purposes of the study, up to a maximum of 1 year (if available) following hospital discharge.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient Mortality</measure>
    <time_frame>28 days &amp; end of follow-up</time_frame>
    <description>Assessment of patient mortality at 28 days, with subsequent determination of survival (i.e., patient status at last known follow-up)</description>
  </other_outcome>
  <other_outcome>
    <measure>Enterocutaneous and Other Fistula</measure>
    <time_frame>Up to 1 year post-injury</time_frame>
    <description>Determination of enterocutaneous/other fistula among study patients during the hospitalization and the follow-up interval</description>
  </other_outcome>
  <other_outcome>
    <measure>Ventral Hernia</measure>
    <time_frame>Up to 1 year follow-up</time_frame>
    <description>Determination of ventral hernia presence during follow-up visits</description>
  </other_outcome>
  <other_outcome>
    <measure>Infection / Abscess / Sepsis</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Assessment of any infection, abscess, or sepsis during the initial and the follow-up periods</description>
  </other_outcome>
  <other_outcome>
    <measure>Bowel Obstruction</measure>
    <time_frame>Up to 1 year follow-up</time_frame>
    <description>Determination of bowel obstruction during the entire available study follow-up period</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Functional Outcomes</measure>
    <time_frame>Up to 1 year follow-up</time_frame>
    <description>Assessment of Glasgow Outcome Scale (GOS) and the Functional Outcome Measures (FOM) during the available follow-up period.
FOM Source: [1] Ohio Dept of Public Safety. Ohio Trauma Registry Data Dictionary. Columbus: 2004.
FOM Scale range: 1 (worst) to 4 (best); GOS Scale: 1 (worst) to 5 (best)
FOM Feeding Subscale
Fully dependent
Partially dependent
Independent w/device
Fully independent
FOM Locomotion Subscale
Fully dependent
Partially dependent
Independent w/device
Fully independent
FOM Expression/Communication Subscale
Fully dependent
Partially dependent
Independent w/device
Fully independent
Glasgow Outcome Scale:
Death
Persistent vegetative state: Minimal responsiveness
Severe disability: Conscious but disabled; dependent on others for daily support
Moderate disability: Disabled but independent; can work in sheltered setting
Good recovery: Resumption of normal life despite minor deficits</description>
  </other_outcome>
  <other_outcome>
    <measure>Would Complication</measure>
    <time_frame>Up to 1 year follow-up period</time_frame>
    <description>Tracking of wound infection, dehiscence, hernia, or any other would-related complication of complaint</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Open Abdomen</condition>
  <condition>Abdominal Adhesions</condition>
  <condition>Trauma</condition>
  <condition>Wounds and Injury</condition>
  <arm_group>
    <arm_group_label>Seprafilm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The treatment group will receive Seprafilm while the control group will not receive Seprafilm. Allocation of patients will be in 1:1 ratio.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Seprafilm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group will be treated according to the current standard of care. No seprafilm will be applied in this subset of patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Seprafilm</intervention_name>
    <description>Two sheets of the Seprafilm material will be applied at each reoperation. Each sheet will be cut into 1x1 inch squares and applied to the following anatomic areas:
Two Seprafilm pieces between the liver and the anterior abdominal wall
Four pieces over the exposed bowel surfaces anteriorly
Two slightly staggered pieces of Seprafilm in each colic gutter
Two pieces in the pelvic area.
If any of the above areas involve an anastomosis or bowel repair, then the Seprafilm should be placed at least 1 inch away from the anastomosis and/or bowel repair.</description>
    <arm_group_label>Seprafilm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Trauma patients undergoing DC/OA management for traumatic injury

          -  Age 18+

          -  Life expectancy longer than 48 hours

        Exclusion Criteria:

          -  Prisoners

          -  Pregnant patients

          -  Younger than 18 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanislaw P Stawicki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>32861</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Stawicki SP, Green JM, Martin ND, Green RH, Cipolla J, Seamon MJ, Eiferman DS, Evans DC, Hazelton JP, Cook CH, Steinberg SM; OPUS 12 Foundation, Inc, Multi-Center Trials Group &amp; OASIT Investigators. Results of a prospective, randomized, controlled study of the use of carboxymethylcellulose sodium hyaluronate adhesion barrier in trauma open abdomens. Surgery. 2014 Aug;156(2):419-30. doi: 10.1016/j.surg.2014.03.007. Epub 2014 Mar 15.</citation>
    <PMID>24962185</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2012</study_first_submitted>
  <study_first_submitted_qc>May 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2012</study_first_posted>
  <results_first_submitted>May 10, 2014</results_first_submitted>
  <results_first_submitted_qc>April 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 30, 2017</results_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>St. Luke's Hospital and Health Network, Pennsylvania</investigator_affiliation>
    <investigator_full_name>Stan Stawicki</investigator_full_name>
    <investigator_title>Associate Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>Open Abdomen</keyword>
  <keyword>Damage Control</keyword>
  <keyword>Trauma</keyword>
  <keyword>Wound healing</keyword>
  <keyword>Gun shot wounds</keyword>
  <keyword>Stab wounds</keyword>
  <keyword>Automobile accidents</keyword>
  <keyword>Wounds and Injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Tissue Adhesions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Currently, the only available data is de-identified dataset without any linkages to the original data. Data storage currently past record-keeping requirements. Study was permanently closed in June 2014.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Seprafilm Group</title>
          <description>Patient who randomized to this group received seprafilm at the end of each consecutive operation; Seprafilm from each previous operation was washed out at the beginning of each subsequent re-operation.</description>
        </group>
        <group group_id="P2">
          <title>No Seprafilm Group</title>
          <description>Patients randomized to this group received no Seprafilm; Abdominal washout at the beginning of each procedure was performed in a fashion identical that in the Seprafilm Group.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Seprafilm</title>
          <description>The treatment group will receive Seprafilm while the control group will not receive Seprafilm. Allocation of patients will be in approximately 1:1 ratio.
Seprafilm: Two sheets of the Seprafilm material will be applied at each reoperation. Each sheet will be cut into 1x1 inch squares and applied to the following anatomic areas:
Two Seprafilm pieces between the liver and the anterior abdominal wall
Four pieces over the exposed bowel surfaces anteriorly
Two slightly staggered pieces of Seprafilm in each colic gutter
Two pieces in the pelvic area.
If any of the above areas involve an anastomosis or bowel repair, then the Seprafilm should be placed at least 1 inch away from the anastomosis and/or bowel repair.</description>
        </group>
        <group group_id="B2">
          <title>No Seprafilm</title>
          <description>Patients in this group will not receive Seprafilm during re-operations. Otherwise, their surgical management will be identical to the Seprafilm Group.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.4" spread="16.7"/>
                    <measurement group_id="B2" value="40.2" spread="16.3"/>
                    <measurement group_id="B3" value="40.3" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adhesion Characteristics</title>
        <description>Zuhlke adhesion score (1 - minimum to 4 - maximum)
= filmy adhesions, easy to separate by blunt dissection
= stronger adhesions; blunt dissection possible, partly sharp dissection necessary; beginning of vascularization
= strong adhesions; lysis possible by sharp dissection only; clear vascularization
= very strong adhesions; lysis possible by sharp dissection only; organs strongly attached with severe adhesions; damage to organs hardly preventable</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Seprafilm</title>
            <description>Operation Number Zuhlke scores (mean / standard error) Operation #1 1.06 / 0.24 Operation #2 1.13 / 0.34 Operation #3 1.54 / 0.69 Operation #4 1.39 / 0.49 Operation #5 1.21 / 0.39 Operation #6 1.50 / 0.77 Operation #7 1.38 / 0.25</description>
          </group>
          <group group_id="O2">
            <title>No Seprafilm</title>
            <description>Operation Number Zuhlke scores (mean / standard error) Operation #1 1.08 / 0.28 Operation #2 1.08 / 0.28 Operation #3 1.19 / 0.32 Operation #4 1.63 / 0.58 Operation #5 2.33 / 0.82 Operation #6 2.92 / 0.83 Operation #7 2.84 / 0.23</description>
          </group>
        </group_list>
        <measure>
          <title>Adhesion Characteristics</title>
          <description>Zuhlke adhesion score (1 - minimum to 4 - maximum)
= filmy adhesions, easy to separate by blunt dissection
= stronger adhesions; blunt dissection possible, partly sharp dissection necessary; beginning of vascularization
= strong adhesions; lysis possible by sharp dissection only; clear vascularization
= very strong adhesions; lysis possible by sharp dissection only; organs strongly attached with severe adhesions; damage to organs hardly preventable</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Zuhlke Adhesion Score</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Zuhlke Adhesion Score</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Operation 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="0.24"/>
                    <measurement group_id="O2" value="1.08" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Operation 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="0.34"/>
                    <measurement group_id="O2" value="1.08" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Operation 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="0.69"/>
                    <measurement group_id="O2" value="1.19" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Operation 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="0.49"/>
                    <measurement group_id="O2" value="1.63" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Operation 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" spread="0.39"/>
                    <measurement group_id="O2" value="2.33" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Operation 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.77"/>
                    <measurement group_id="O2" value="2.92" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Operation 7+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="0.25"/>
                    <measurement group_id="O2" value="2.84" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wound Healing Characteristics</title>
        <description>There will not be a fixed duration of outpatient follow-up (fixed follow-up in trauma patients is not practical due to the unpredictable nature of trauma population), an average (mean) follow-up will be determined for the entire cohort of patients for the purposes of the study, up to a maximum of 1 year (if available) following hospital discharge.</description>
        <time_frame>Participants will be followed until their open abdomen is closed. Depending on the nature and severity of the wound, this period may last as long as 1 year after the patient has been discharged.</time_frame>
        <population>Wound areas for Seprafilm and &quot;No Seprafilm&quot; groups were obtained serially, by measuring each wound horizontally and vertically and multiplying measurements (in centimeters) to determine the estimated area in cm squared.</population>
        <group_list>
          <group group_id="O1">
            <title>Wound Sizes: Seprafilm</title>
            <description>Wound size characteristics (estimated area = &quot;Width x Length&quot; in centimeters squared) for patients who received Seprafilm</description>
          </group>
          <group group_id="O2">
            <title>Wound Sizes: No Seprafilm</title>
            <description>Wound size characteristics (estimated area = &quot;Width x Length&quot; in centimeters squared) for patients who did not receive Seprafilm</description>
          </group>
        </group_list>
        <measure>
          <title>Wound Healing Characteristics</title>
          <description>There will not be a fixed duration of outpatient follow-up (fixed follow-up in trauma patients is not practical due to the unpredictable nature of trauma population), an average (mean) follow-up will be determined for the entire cohort of patients for the purposes of the study, up to a maximum of 1 year (if available) following hospital discharge.</description>
          <population>Wound areas for Seprafilm and &quot;No Seprafilm&quot; groups were obtained serially, by measuring each wound horizontally and vertically and multiplying measurements (in centimeters) to determine the estimated area in cm squared.</population>
          <units>Square Centimeters (cm2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Composite wound size (cm2): Time 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="419" spread="238"/>
                    <measurement group_id="O2" value="393" spread="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Composite wound size (cm2): Week 02</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282" spread="224"/>
                    <measurement group_id="O2" value="322" spread="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Composite wound size (cm2): Week 04</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223" spread="278"/>
                    <measurement group_id="O2" value="218" spread="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Composite wound size (cm2): Week 08</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" spread="70"/>
                    <measurement group_id="O2" value="210" spread="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Composite wound size (cm2): Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" spread="5"/>
                    <measurement group_id="O2" value="116" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Composite wound size (cm2): Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66" spread="30"/>
                    <measurement group_id="O2" value="148" spread="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Composite wound size (cm2): Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" spread="55"/>
                    <measurement group_id="O2" value="59" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Mortality</title>
        <description>Assessment of patient mortality at 28 days, with subsequent determination of survival (i.e., patient status at last known follow-up)</description>
        <time_frame>28 days &amp; end of follow-up</time_frame>
        <population>Note: Both mortalities in the Seprafilm group involved withdrawal of care as per previously stated patient wishes.</population>
        <group_list>
          <group group_id="O1">
            <title>Seprafilm</title>
            <description>The treatment group will receive Seprafilm.</description>
          </group>
          <group group_id="O2">
            <title>No Seprafilm</title>
            <description>This group will be treated according to the current standard of care. No seprafilm will be applied in this subset of patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Mortality</title>
          <description>Assessment of patient mortality at 28 days, with subsequent determination of survival (i.e., patient status at last known follow-up)</description>
          <population>Note: Both mortalities in the Seprafilm group involved withdrawal of care as per previously stated patient wishes.</population>
          <units>Mortalities</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Enterocutaneous and Other Fistula</title>
        <description>Determination of enterocutaneous/other fistula among study patients during the hospitalization and the follow-up interval</description>
        <time_frame>Up to 1 year post-injury</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Seprafilm</title>
            <description>The treatment group will receive Seprafilm.</description>
          </group>
          <group group_id="O2">
            <title>No Seprafilm</title>
            <description>This group will be treated according to the current standard of care. No seprafilm will be applied in this subset of patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Enterocutaneous and Other Fistula</title>
          <description>Determination of enterocutaneous/other fistula among study patients during the hospitalization and the follow-up interval</description>
          <units>Total events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Ventral Hernia</title>
        <description>Determination of ventral hernia presence during follow-up visits</description>
        <time_frame>Up to 1 year follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Seprafilm</title>
            <description>The treatment group will receive Seprafilm.</description>
          </group>
          <group group_id="O2">
            <title>No Seprafilm</title>
            <description>This group will be treated according to the current standard of care. No seprafilm will be applied in this subset of patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Ventral Hernia</title>
          <description>Determination of ventral hernia presence during follow-up visits</description>
          <units>Hernia</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Infection / Abscess / Sepsis</title>
        <description>Assessment of any infection, abscess, or sepsis during the initial and the follow-up periods</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Seprafilm</title>
            <description>The treatment group will receive Seprafilm.</description>
          </group>
          <group group_id="O2">
            <title>No Seprafilm</title>
            <description>This group will be treated according to the current standard of care. No seprafilm will be applied in this subset of patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Infection / Abscess / Sepsis</title>
          <description>Assessment of any infection, abscess, or sepsis during the initial and the follow-up periods</description>
          <units>Total events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Bowel Obstruction</title>
        <description>Determination of bowel obstruction during the entire available study follow-up period</description>
        <time_frame>Up to 1 year follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Seprafilm</title>
            <description>The treatment group will receive Seprafilm.</description>
          </group>
          <group group_id="O2">
            <title>No Seprafilm</title>
            <description>This group will be treated according to the current standard of care. No seprafilm will be applied in this subset of patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Bowel Obstruction</title>
          <description>Determination of bowel obstruction during the entire available study follow-up period</description>
          <units>Bowel obstruction</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Functional Outcomes</title>
        <description>Assessment of Glasgow Outcome Scale (GOS) and the Functional Outcome Measures (FOM) during the available follow-up period.
FOM Source: [1] Ohio Dept of Public Safety. Ohio Trauma Registry Data Dictionary. Columbus: 2004.
FOM Scale range: 1 (worst) to 4 (best); GOS Scale: 1 (worst) to 5 (best)
FOM Feeding Subscale
Fully dependent
Partially dependent
Independent w/device
Fully independent
FOM Locomotion Subscale
Fully dependent
Partially dependent
Independent w/device
Fully independent
FOM Expression/Communication Subscale
Fully dependent
Partially dependent
Independent w/device
Fully independent
Glasgow Outcome Scale:
Death
Persistent vegetative state: Minimal responsiveness
Severe disability: Conscious but disabled; dependent on others for daily support
Moderate disability: Disabled but independent; can work in sheltered setting
Good recovery: Resumption of normal life despite minor deficits</description>
        <time_frame>Up to 1 year follow-up</time_frame>
        <population>Please see Outcome Measure Description [above] for exact measure(s) utilized, including measurement scale(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Seprafilm</title>
            <description>The treatment group will receive Seprafilm.</description>
          </group>
          <group group_id="O2">
            <title>No Seprafilm</title>
            <description>This group will be treated according to the current standard of care. No seprafilm will be applied in this subset of patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Functional Outcomes</title>
          <description>Assessment of Glasgow Outcome Scale (GOS) and the Functional Outcome Measures (FOM) during the available follow-up period.
FOM Source: [1] Ohio Dept of Public Safety. Ohio Trauma Registry Data Dictionary. Columbus: 2004.
FOM Scale range: 1 (worst) to 4 (best); GOS Scale: 1 (worst) to 5 (best)
FOM Feeding Subscale
Fully dependent
Partially dependent
Independent w/device
Fully independent
FOM Locomotion Subscale
Fully dependent
Partially dependent
Independent w/device
Fully independent
FOM Expression/Communication Subscale
Fully dependent
Partially dependent
Independent w/device
Fully independent
Glasgow Outcome Scale:
Death
Persistent vegetative state: Minimal responsiveness
Severe disability: Conscious but disabled; dependent on others for daily support
Moderate disability: Disabled but independent; can work in sheltered setting
Good recovery: Resumption of normal life despite minor deficits</description>
          <population>Please see Outcome Measure Description [above] for exact measure(s) utilized, including measurement scale(s).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Self-Feeding Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.93" spread="1.44"/>
                    <measurement group_id="O2" value="3.25" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Locomotion Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.24"/>
                    <measurement group_id="O2" value="2.25" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Expression / Communication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.47" spread="1.13"/>
                    <measurement group_id="O2" value="3.45" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glasgow Outcome Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.07" spread="0.80"/>
                    <measurement group_id="O2" value="3.40" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Would Complication</title>
        <description>Tracking of wound infection, dehiscence, hernia, or any other would-related complication of complaint</description>
        <time_frame>Up to 1 year follow-up period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Seprafilm</title>
            <description>The treatment group will receive Seprafilm.</description>
          </group>
          <group group_id="O2">
            <title>No Seprafilm</title>
            <description>This group will be treated according to the current standard of care. No seprafilm will be applied in this subset of patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Would Complication</title>
          <description>Tracking of wound infection, dehiscence, hernia, or any other would-related complication of complaint</description>
          <units>Wound complication</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Daily assessments for adverse events (AE) were performed during the initial hospitalization phase for each patient; Additional AE screening was done during outpatient visits; AE data were collected during up to 1 year voluntary follow-up.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Seprafilm Group</title>
          <description>Patient who randomized to this group received seprafilm at the end of each consecutive operation; Seprafilm from each previous operation was washed out at the beginning of each subsequent re-operation.</description>
        </group>
        <group group_id="E2">
          <title>No Seprafilm Group</title>
          <description>Patients randomized to this group received no Seprafilm; Abdominal washout at the beginning of each procedure was performed in a fashion identical that in the Seprafilm Group.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Mortality</sub_title>
                <description>Two patients (2/17) in the Seprafilm group experienced 28-day mortality; One patient (1/13) in No Seprafilm group experienced 28-day mortality; Mortality was attributed to high injury severity and physiologic acuity; Not associated with the study.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <description>5/17 patients in Seprafilm group developed respiratory failure; 5/13 in No Seprafilm group developed respiratory failure; All instances of respiratory failure were related to injury severity / physiologic acuity; Not related to study conduct</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stanislaw P. Stawicki, M.D.</name_or_title>
      <organization>St. Luke's University Health Network</organization>
      <phone>484-526-4426</phone>
      <email>stanislaw.stawicki@sluhn.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

